Discover
MCRB
Seres Therapeutics, Inc.
7.94
2 x 5.64
2 x 9.81
bid
ask
+
0.05
0.63%
2 @ 04:00 PM
7.94 +0.00 (0.00%)
| Ytd | -46.64% | |
| 1y | -25.79% |
7.63
day range
8.00
5.31
52 week range
29.98
| Open | 7.82 | Prev Close | 7.89 | Low | 7.63 | High | 8.00 | Mkt Cap | 76.89M |
| Vol | 150.63K | Avg Vol | 69.88K | EPS | -5.20 | P/E | N/A | Forward P/E | -1.75 |
| Beta | 2.05 | Short Ratio | 5.18 | Inst. Own | 37.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 7.31 | 200-d Avg | 12.63 | 1yr Est | 3.87 |
MCRB News
benzinga.com
Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-15
The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long histor
globenewswire.com
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Tri
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leadi
benzinga.com
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo
benzinga.com
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:M
benzinga.com
Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installm
Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live b